Reduced ability to metabolize cognitive enhancer 5-(3-methoxyphenyl)-3-(5-methyl1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine (AC-3933)

Disease overview

This is a pharmacokinetic-based condition in which there is variability in how a drug is metabolized. For example, Beagle dogs are classified as either extensive metabolizers or poor metabolizers of cognitive enhancer drug 5-(3-methoxyphenyl)-3-(5-methyl1,2,4-oxadiazol-3-yl)-2-oxo-1,2-dihydro-1,6-naphthyridine (AC-3933).

Gene name

CYP1A2

Inheritance

Autosomal recessive

Signs and symptoms

There are no clinical signs associated with this condition.

How is it diagnosed

Genetic testing can determine if this mutation is present.

Breeds at higher risk

Citations

Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):413-21. PMID: 7920209.

Disclaimer

Disease diagnosis and treatment should always be performed by a veterinarian. The following information is for educational purposes only.